跳至主要内容
临床试验/NCT06695429
NCT06695429招募中不适用

Suplementación Con Zumo de REmolacha Para Prevenir la Nefropatía Asociada a Contraste Durante la hospitalización Por Síndrome Coronario Agudo Sin elevación Del ST

Hospital General Universitario Santa Lucia1 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2024年10月7日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
130
试验地点
1
主要终点
Number of Participants with Contrast-induced nephropathy

研究概览

简要总结

The goal of this study is to compare the possible beneficial effect of beetroot juice supplementation versus the usual management during hospitalization to prevent contrast-induced nephropathy after cardiac catheterizations.

The study includes patients diagnosed with non-ST elevation acute coronary syndrome with a possible indication for catheterism and high risk of kidney injury related to iodinated contrast.

The intervention group will drink 500 mL (2 glasses daily, at breakfast and dinner) of beetroot juice added to the usual diet for 7 days or until hospital discharge and will receive the recommendation to maintain a diet rich in inorganic nitrates. The control group will receive the usual diet and recommendations. In both cases, other therapies will be prescribed to prevent contrast-induced nephropathy (hydration and statins) if there is no contraindication.

Our hypothesis is that a compound present in beetroot juice, inorganic nitrates, can prevent the deterioration of kidney function related to contrast due to its vasodilatory effect, in addition to improving the subsequent prognosis of coronary heart disease due to its anti-inflammatory and antiproliferative effects, protector of the endothelium and inhibitor of platelet aggregation. Beetroot juice could also be beneficial in this context due to the antioxidant effect of the betalains it contains.

详细描述

Contrast-induced nephropathy (CIN) is a common complication in patients admitted for acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI).

Although the deterioration of renal function is generally reversible, avoiding CIN is of great importance as it is associated with worse prognosis, including greater need for renal replacement therapies and greater mortality.

Inorganic nitrates (NO3-) are the most promising therapy to prevent CIN, due to their ability to be metabolized to nitric oxide (NO), whose vasodilator effect protects renal perfusion. In addition, NO has other potential benefits in ACS due to its anti-inflammatory, antiproliferative, endothelium protective, and platelet aggregation inhibitor effects.

The recent NITRATE-CIN study has shown that the administration of 12 mmol/24 h of KNO3 for 5 days to patients admitted for non-ST elevation (NSTE) ACS undergoing PCI not only significantly reduced the risk of CIN, but also prevented the deterioration of kidney function and significantly reduced major cardiovascular complications (MACE) during follow-up.

However, there is currently no comercially available presentation for KNO3 and its administration could be associated with hyperkalemia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Diagnosis of Acute Coronary Syndrome without persistent ST segment elevation, with recommendation for invasive management according to the actual Clinical practice guidelines
  • •At least moderate or high risk of nephropathy associated with iodinated contrast (Mehran score (without including contrast volume) ≥ 6).

排除标准

  • •<18 years old or without capacity to give consent.
  • •Refusal to participate in the study.
  • •Known hypersensitivity to beetroot or any of its allergens.
  • •Pregnant.
  • •Inability to take food orally
  • •Serious illnesses (not related to ACS or kidney failure), which limits their life expectancy to a period predictably less than 1 year.
  • •On dialysis or predialysis at the time of inclusion.
  • •ACS with persistent ST segment elevation before inclusion.
  • •Shock or inotrope dependence at the time of inclusion
  • •PCI already performed before inclusion.
  • •Patients receiving intravenous nitroglycerin for > 1 hour before inclusion

研究组 & 干预措施

Beetroot juice supplementation

Experimental

Supplementation with 500 mL of beetroot juice daily in 2 doses of 250 mL, for 7 days, or until hospital discharge, and a recommendation to maintain a diet rich in vegetables with high nitrate content after discharge.

(In addition to usual treatment with hydration and statins to prevent contrast induced nephropathy)

干预措施: Beetroot juice (Dietary Supplement)

Usual care

No Intervention

Usual treatment with hydration and statins to prevent contrast induced nephropathy

结局指标

主要结局

Number of Participants with Contrast-induced nephropathy

时间窗: 7 days

Defined as an increase in serum creatinine ≥0.3 mg/dL in the first 48 hours or ≥1.5 times the baseline value during the week after the first PCI performed on admission

次要结局

  • Number of Participants with In-hospital MACE (Major adverse cardiovascular events)(Up to 30 days)
  • Number of Participants with In-hospital hyperkalemia(Up to 30 days)
  • Rate of Drop-out from beetroot juice during hospitalization(7 days)
  • Relative and absolute changes from baseline of serum creatinine and estimated glomerular filtration rate during follow-up(1 year)
  • Number of Participants with Need for renal replacement therapy(1 year)
  • Number of Participants with MACE during follow-up(1 year)

研究者

发起方
Hospital General Universitario Santa Lucia
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jose Manuel Andreu Cayuelas

Principal Investigator

Hospital General Universitario Santa Lucia

研究点 (1)

Loading locations...

相似试验